Literature DB >> 25432594

Prognostic factors in resectable pathological N2 disease of non-small cell lung cancer.

Chen-Ping Hsieh, Jui-Ying Fu, Yun-Hen Liu, Cheng-Ta Yang, Ming-Ju Hsieh, Ying-Huang Tsai, Yi-Cheng Wu, Ching-Yang Wu1.   

Abstract

BACKGROUND: N2-positive non-small cell lung cancer (NSCLC) exhibits extremely low survival rates. The role of surgery in operable locally advanced N2 NSCLC remains controversial. In this study, we tried to analyze the role of surgery in resectable N2 NSCLC and the relationship between survival and clinico-pathologic factors from a pathologic point of view.
METHODS: 108 resectable pathologic N2-positive NSCLC patients, diagnosed from January 2005 to July 2012, were enrolled in this study. We retrospectively reviewed the medical records, image studies, and pathology reports to collect the clinico-pathologic factors in these patients.
RESULTS: Those who received lobectomy (p = 0.002) and had a metastatic lymph node ratio less than 0.4 (p = 0.01) had a better overall survival rate. In addition, our study also showed that perineural invasion may play a significant role in disease-free survival (p = 0.01)
CONCLUSIONS: Metastatic lymph node ratio greater than 0.4 and non-anatomic resection were poor prognostic factors for disease-free survival. Anatomic resection for selected N2 patients may play a crucial role in the overall survival rate. Perineural invasion showed an adverse impact on disease-free survival, but further investigation is warranted.

Entities:  

Mesh:

Year:  2015        PMID: 25432594     DOI: 10.4103/2319-4170.145765

Source DB:  PubMed          Journal:  Biomed J        ISSN: 2319-4170            Impact factor:   4.910


  2 in total

1.  Lymph node ratio is a prognostic factor for non-small cell lung cancer.

Authors:  Guangyuan Sun; Lei Xue; Mingdong Wang; Xuewei Zhao
Journal:  Oncotarget       Date:  2015-10-20

2.  Autonomic nervous infiltration positively correlates with pathological risk grading and poor prognosis in patients with lung adenocarcinoma.

Authors:  Jing-Xin Shao; Bo Wang; Yi-Nan Yao; Zhi-Jie Pan; Qian Shen; Jian-Ying Zhou
Journal:  Thorac Cancer       Date:  2016-07-12       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.